Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial

IMPORTANCE: The efficacy of niraparib maintenance therapy with an individualized starting dose (ISD) warrants further investigation in a broad population with newly diagnosed advanced ovarian cancer (aOC), including patients without postoperative residual disease. OBJECTIVE: To evaluate the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ning, Zhu, Jianqing, Yin, Rutie, Wang, Jing, Pan, Lingya, Kong, Beihua, Zheng, Hong, Liu, Jihong, Wu, Xiaohua, Wang, Li, Huang, Yi, Wang, Ke, Zou, Dongling, Zhao, Hongqin, Wang, Chunyan, Lu, Weiguo, Lin, An, Lou, Ge, Li, Guiling, Qu, Pengpeng, Yang, Hongying, Zhang, Yu, Cai, Hongbing, Pan, Yueyin, Hao, Min, Liu, Ziling, Cui, Heng, Yang, Yingjie, Yao, Shuzhong, Zhen, Xiaoa, Hang, Wenzhao, Hou, Jianmei, Wang, Juan, Wu, Lingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346505/
https://www.ncbi.nlm.nih.gov/pubmed/37440217
http://dx.doi.org/10.1001/jamaoncol.2023.2283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346505/
https://www.ncbi.nlm.nih.gov/pubmed/37440217
http://dx.doi.org/10.1001/jamaoncol.2023.2283

Ejemplares similares